(Q50967762)

26 March 2018

title

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. (English)

1 reference

26 March 2018

comprehensive genomic profiling

main subject

cholangiocarcinoma

0 references

1 reference

4

David M Jones

1 reference

26 March 2018

author name string

Hwajeong Lee

1

1 reference

26 March 2018

Kai Wang

2

1 reference

26 March 2018

Adrienne Johnson

3

1 reference

26 March 2018

Siraj M Ali

5

1 reference

26 March 2018

Julia A Elvin

6

1 reference

26 March 2018

Roman Yelensky

7

1 reference

26 March 2018

Doron Lipson

8

1 reference

26 March 2018

Vincent A Miller

9

1 reference

26 March 2018

Philip J Stephens

10

1 reference

26 March 2018

Milind Javle

11

1 reference

26 March 2018

Jeffrey S Ross

12

1 reference

26 March 2018

language of work or name

English

0 references

publication date

23 October 2015

1 reference

26 March 2018

Journal of Clinical Pathology

published in

1 reference

26 March 2018

volume

69

1 reference

26 March 2018

page(s)

403-408

1 reference

26 March 2018

issue

5

1 reference

26 March 2018

The epidemiology of cholangiocarcinoma

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Outcome of treatment for distal bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Epidemiology and risk factors of biliary tract and primary liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Cholangiocarcinoma: modern advances in understanding a deadly old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Current surgical treatment for bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Palliation: treating patients with inoperable biliary tract and primary liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Emerging drugs for biliary cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Genetics of Opisthorchis viverrini-related cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Cholangiocarcinoma: molecular pathways and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Targeted therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

The NF1 gene revisited - from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Molecular landscape of pancreatic cancer: implications for current clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Histological Characterization of Biliary Intraepithelial Neoplasia with respect to Pancreatic Intraepithelial Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Molecular mechanisms of bile duct development

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

Analysis of extrahepatic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2015-203394

10.1136/JCLINPATH-2015-203394

21 January 2018

Identifiers

DOI

1 reference

26 March 2018

release_a5rt6zqbtjam7mbzfvfabvehs4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a5rt6zqbtjam7mbzfvfabvehs4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

26500333

1 reference

26 March 2018